跳至主要内容
临床试验/NL-OMON53724
NL-OMON53724招募中不适用

Magnesium Supplementation as a Strategy to Reduce Serum Calcification Propensity and Vascular Stiffness in People with Type 2 Diabetes. - Mg-MAC

Amsterdam UMC0 个研究点目标入组 74 人开始时间: 待定最近更新:

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
74

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • age 50-80 years;
  • Diabetes Mellitus Type 2;
  • Presence of a predominantly medial arterial calcification pattern on a
  • previously conducted CT scan of the legs;
  • Carotid-femoral pulse wave velocity higher than 12 meter per seconde;
  • Ability to provide informed consent prior to initiating screening visit
  • procedures.

排除标准

  • Myasthenia Gravis;
  • Use of medications that might interact with magnesium supplements
  • (levothyroxine, osteoporosis medications tiludronate and alendronate, warfarin);
  • Advanced diabetes complications (proliferative retinopathy, disabling
  • polyneuropathy, nephropathy with an estimated glomerular filtration rate
  • (eGFR), calculated with the Jaffé method according to the Chronic Kidney
  • Disease Epidemiology Collaboration equation <15 mL/min/1.73m2 or chronic
  • dialysis, cardiac complications);
  • Uncontrolled hyperthyroidism or active parathyroid disease;
  • Chronic diarrheal disease or inflammatory bowel diseases;
  • Congestive heart failure, bradycardia with a resting heart rate below 60 and
  • systolic blood pressure less than 90 mmHg;
  • Atrial Fibrillation;
  • Previous aortic surgery;
  • Severe hepatic insufficiency;
  • Malignancy or other non-cardiac conditions limiting life expectancy to <3 years;
  • Using food supplements that contain magnesium, or unwilling to stop two weeks
  • before randomization;
  • Mental or legal incapacitation to provide informed consent;
  • Plasma magnesium concentration*>*2.6*mg/dL or < 1.5 mg/dL at screening.

研究者

发起方
Amsterdam UMC

相似试验